安旭生物2024年报解读：稳健经营筑底 创新驱动蓄力长远发展

Core Insights - Anxu Bio is a technology-driven POCT (point-of-care testing) company with nine technology platforms covering various testing fields, forming a comprehensive industry chain of raw materials, reagents, and instruments [1] - In 2024, the company invested 101 million yuan in R&D, accounting for 18.67% of its revenue, and achieved significant advancements in product certifications and patents [1][2] - The company reported a revenue of 541 million yuan in 2024, a year-on-year increase of 7.42%, and a net profit of 192 million yuan, reflecting a substantial growth of 35.85% [4] R&D and Product Development - Anxu Bio's R&D efforts led to the acquisition of 44 new patents and 592 international certifications, enhancing its product matrix and technological capabilities [1] - The company has recently received domestic medical device registration for several products, indicating progress in expanding its domestic market [1] Financial Performance and Shareholder Returns - Since its listing in 2021, Anxu Bio has distributed a total of 794 million yuan in dividends, with a planned cash dividend of 8 yuan per 10 shares for 2024, amounting to 15.25 million yuan, which represents 79.30% of the net profit [2] Market Expansion and Strategic Initiatives - Anxu Bio is extending its business into the pet medical market through its subsidiary, aiming to leverage its experience in pet testing products [2] - The company has launched a chronic disease management app, enhancing its product offerings in home health management and facilitating seamless health data utilization [2]